Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UmbrellaMAX Extension Study in Cancer Patients
NCT05862285Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2023
- Primary completion
- Mar 2033
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of ipatasertib, tiragolumab, atezolizumab, bevacizumab, entrectinib in cancer, sponsored by Roche. Started Jun 2023; status: recruiting.
02
Drugs
ipatasertibtiragolumabatezolizumabbevacizumabentrectinib
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05862285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862285.